Novel strategies for organ sparing in patients with complete response to radiochemotherapy in Iocally advanced rectal cancer
From 01-01-2014 to 31-12-2017
Description
Novel strategies for organ sparing in patients with complete response to radiochemotherapy in Iocally advanced rectal cancer
Rectal cancer accounts for about 30% of all colorectal tumours, which are the second leading cause of cancer-related death in the Western world. About 70 % of the patients with rectal cancer present with stage II-III disease at diagnosis. The standard treatment for these patients is neo-adjuvant radiochemotherapy (RCT) followed by a total mesorectal excision (TME). Several studies however indicate that up to 20% of these patients achieve pathologic complete response (pCR) after RCT and might therefore be spared from surgery. The primary objective of this study is therefore to develop reliable methods for identifying this sub-group of patients.
For this purpose we will:
I. Assess the sensitivity and specificity of diffusion weighted MRI (DW-MRI), Gadofosveset-MRI (GDF-MRI) and 18F-FDG-PET in the presurgical response evaluation, confirming promising preliminary results.
II. Set up a response signature based on the clinical, imaging data and the molecular markers evaluated in a first clinical study (explorative study).
III. Validate the power of the signature in a validation study in which patients are selected for surgery or the ‘wait and see’ option based on this response signature.
With this project, we hope to make a leap forward in the individualization of the treatment for patients with locally advanced rectal cancer. Identification of patients with a complete response can spare these patients from the invasive surgery and significantly improve their quality of life.
Team
- Bart De Moor, Co-promoter
- R. Weytjens, Co-promoter (External)
- Karin Haustermans, Promoter (External)
- Inge Thijs, Team member
Financing
Funding: IWT - Agentschap voor Innovatie door Wetenschap en Technologie
Program/Grant Type: IWT TBM - VLAIO TBM Projects Applied Biomedical Research with a Primary Social finality
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.